TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

被引：0
|
作者：
D. Ferraro
D. Goldstein
R. L. O’Connell
J. R. Zalcberg
K. M. Sjoquist
N. C. Tebbutt
P. Grimison
S. McLachlan
L. L. Lipton
P. Vasey
V. J. Gebski
C. Aiken
M. Cronk
S. Ng
C. S. Karapetis
J. Shannon
机构：
[1] University of Sydney,National Health and Medical Research Council Clinical Trials Centre
[2] University of New South Wales,Prince of Wales Clinical School
[3] Monash University,Department of Epidemiology and Preventive Medicine
[4] Austin Health,Haematology and Oncology Clinics of Australasia
[5] Chris O’Brien Lifehouse,Department of Medical Oncology
[6] St Vincents Hospital,Department of Pathology
[7] University of Melbourne,undefined
[8] Western Health,undefined
[9] Wesley Medical Centre,undefined
[10] Nambour General Hospital,undefined
[11] Flinders University,undefined
[12] Nepean Cancer Care Centre,undefined
[13] University of Melbourne,undefined
[14] Sir Charles Gairdner Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Biliary tract cancer; KRAS; Panitumumab; Chemotherapy; Phase II trial; Cancer antigen 19.9;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：361 / 367
页数：6
相关论文
共 50 条
  • [21] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [22] A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor
    Limon, Dror
    Amiel, Alexandra
    Haim, Shaked Even
    Gordon, Noa
    Tschernichovsky, Roi
    Stemmer, Salomon
    Gal, Omer
    Laviv, Yosef
    Kanner, Andrew
    Siegal, Tali
    Yust-Katz, Shlomit
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [23] Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
    Belkouz, Ali
    de Vos-Geelen, Judith
    Mathot, Ron A. A.
    Eskens, Ferry A. L. M.
    van Gulik, Thomas M.
    van Oijen, Martijn G. H.
    Punt, Cornelis J. A.
    Wilmink, Johanna W.
    Klumpen, Heinz-Josef
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 634 - 639
  • [24] Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
    Ali Belkouz
    Judith de Vos-Geelen
    Ron A. A. Mathôt
    Ferry A. L. M. Eskens
    Thomas M. van Gulik
    Martijn G. H. van Oijen
    Cornelis J. A. Punt
    Johanna W. Wilmink
    Heinz-Josef Klümpen
    British Journal of Cancer, 2020, 122 : 634 - 639
  • [25] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Brose, Marcia S.
    Cohn, Allen L.
    Mier, James
    Di Simone, Christopher
    Hyman, David M.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Schmidt, Emmett V.
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Aghajanian, Carol
    Taylor, Matthew
    LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
  • [26] Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
    Moore, Kathleen N.
    Secord, Angeles Alvarez
    Geller, Melissa A.
    Miller, David Scott
    Cloven, Noelle
    Fleming, Gini F.
    Hendrickson, Andrea E. Wahner
    Azodi, Masoud
    DiSilvestro, Paul
    Oza, Amit M.
    Cristea, Mihaela
    Berek, Jonathan S.
    Chan, John K.
    Rimel, Bobbie J.
    Matei, Daniela E.
    Li, Yong
    Sun, Kaiming
    Luptakova, Katarina
    Matulonis, Ursula A.
    Monk, Bradley J.
    LANCET ONCOLOGY, 2019, 20 (05): : 636 - 648
  • [27] CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial
    Saunders, M. P.
    Graham, J.
    Cunningham, D.
    Plummer, R.
    Church, D.
    Kerr, R.
    Cook, S.
    Zheng, S.
    La Thangue, N.
    Kerr, D.
    ESMO OPEN, 2022, 7 (06)
  • [28] Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
    Wang, J-S.
    Wu, T.
    Hong, Y-G.
    Guo, Y-Z.
    Luo, S-X.
    Li, N.
    Cheng, Y-F.
    Li, B-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S910 - S911
  • [29] Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
    Lee, Jeeyun
    Park, Se Hoon
    Chang, Heung-Moon
    Kim, Jun Suk
    Choi, Hye Jin
    Lee, Myung Ah
    Jang, Joung Soon
    Jeung, Hei Cheul
    Kang, Jung Hun
    Lee, Hyun Woo
    Shin, Dong Bok
    Kang, Hye Jin
    Sun, Jong-Mu
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    LANCET ONCOLOGY, 2012, 13 (02): : 181 - 188
  • [30] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Jamie E. Chaft
    Filiz Oezkan
    Mark G. Kris
    Paul A. Bunn
    Ignacio I. Wistuba
    David J. Kwiatkowski
    Dwight H. Owen
    Yan Tang
    Bruce E. Johnson
    Jay M. Lee
    Gerard Lozanski
    Maciej Pietrzak
    Michal Seweryn
    Woo Yul Byun
    Katja Schulze
    Alan Nicholas
    Ann Johnson
    Jessica Grindheim
    Stephanie Hilz
    David S. Shames
    Chris Rivard
    Eric Toloza
    Eric B. Haura
    Ciaran J. McNamee
    G. Alexander Patterson
    Saiama N. Waqar
    Valerie W. Rusch
    David P. Carbone
    Nature Medicine, 2022, 28 : 2155 - 2161
12345